Gide advises the EIB on €30 million venture debt financing for TreeFrog Therapeutics

Gide advised the European Investment Bank (EIB) on a €30 million venture debt financing for TreeFrog Therapeutics, a French biotechnology company specializing in cell therapy.

This financing will support the advancement of their main cell therapy program against Parkinson’s disease up to the clinical trial phase. The funds will also be used to strengthen their internal portfolio in other therapeutic areas with significant unmet needs.

The €30 million financing is available in three tranches of €10 million each, with TreeFrog benefiting from a mixed dilutive financing—meaning no principal repayment for the first two tranches—and a risk debt for the final tranche.

The EIB’s investment aligns with the InvestEU objective to encourage research, development, and innovation.

The Gide team comprised Farah El-Bsat, partner, and Romane Chaumeil on financing matters, and Antoine La Gatinais, partner, Donald Davy, counsel, and Axel Azoulay, associate, on corporate matters.